drug
as of 2026-07-01ML-007C-MA QD
at a glance
small molecule
Pre-approval / investigational in the US
Developed by MapLight Therapeutics
1 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
small molecule
Indications
Trials
1
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
NCT07038876Phase 2Active Not Recruiting
KOLs & investigators
1
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
company
trial
indication
indication
indication
indication
indication
KOL
MapLight Therapeutics
personKOL score —